95893-88-2

Basic information

• Product Name: (2-ETHOXY-ETHYL)-(2-NITRO-PHENYL)-AMINE
• Synonyms: (2-ETHOXY-ETHYL)-(2-NITRO-PHENYL)-AMINE;N-(2-ETHOXYETHYL)-2-NITROANILINE
• CAS NO: 95893-88-2
• Molecular Formula: C₁₀H₁₄N₂O₃
• Molecular Weight: 210.23
• Mol File: 95893-88-2.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 144-144.5 °C(Press: 1 Torr)
• Appearance: /
• Density: 1.190±0.06 g/cm3(Predicted)
• PKA: 0.25±0.50(Predicted)
• CAS DataBase Reference: (2-ETHOXY-ETHYL)-(2-NITRO-PHENYL)-AMINE(CAS DataBase Reference)
• NIST Chemistry Reference: (2-ETHOXY-ETHYL)-(2-NITRO-PHENYL)-AMINE(95893-88-2)
• EPA Substance Registry System: (2-ETHOXY-ETHYL)-(2-NITRO-PHENYL)-AMINE(95893-88-2)

Safety Data

• Hazardous Substances Data: 95893-88-2(Hazardous Substances Data)

Usage

General Description

(2-ethoxy-ethyl)-(2-nitro-phenyl)-amine is a chemical compound with the molecular formula C10H14N2O3. It is a yellow crystalline solid with a molecular weight of 214.23 g/mol. (2-ETHOXY-ETHYL)-(2-NITRO-PHENYL)-AMINE is commonly used as an intermediate in the synthesis of pharmaceuticals and organic pigments. It is also used in the manufacturing of dyes and as a reagent in organic synthesis. Additionally, it has potential applications in the field of organic chemistry as a building block for the synthesis of various functionalized compounds. The compound is known to have some toxicological properties and should be handled with caution in laboratory and industrial settings.

Upstream product

• 110-76-9 2-ethoxy-1-ethanamine 
• 88-73-3 2-Chloronitrobenzene 
• 74-96-4 ethyl bromide 
• 4926-55-0 2-[(2-nitrophenyl)amino]ethanol 
• 1493-27-2 ortho-nitrofluorobenzene 

Downstream Products

• 95893-89-3 N-(β-ethoxyethyl)-o-phenylenediamine 
• 87233-54-3 1-(2-ethoxyethyl)-2-chloro-1H-benzimidazole 
• 101953-61-1 N-(2-ethoxyethyl)-2-benzimidazolone 
• 101954-15-8 1-(2-Ethoxy-ethyl)-2-(4-phenyl-piperazin-1-yl)-1H-benzoimidazole 
• 101954-30-7 2-(4-Benzyl-[1,4]diazepan-1-yl)-1-(2-ethoxy-ethyl)-1H-benzoimidazole 
• 87233-79-2 2-(4-benzyl-1-piperazinyl)-1-(2-ethoxyethyl)benzimidazole 
• 101954-16-9 1-(2-Ethoxy-ethyl)-2-(4-phenethyl-piperazin-1-yl)-1H-benzoimidazole 
• 101954-18-1 2-(4-Benzhydryl-piperazin-1-yl)-1-(2-ethoxy-ethyl)-1H-benzoimidazole 
• 1567835-76-0 1-(4-bromophenethyl)-N-(2-((2-ethoxyethyl)amino)phenyl)piperidine-4-carboxamide 
• 1181267-38-8 4-[2-[4-[1-(2-ethoxyethyl)-1H-benzimidazol-2-yl]-1-piperidine]ethyl]-α,α-dimethylphenylacetic acid methyl ester 
• 1567835-77-1 4-[2-[4-[1-(2-ethoxyethyl)-1H-benzimidazol-2-yl]-1-piperidine]ethyl]-α,α-dimethylphenylacetic acid methyl ester hydrochloride 
• 202189-78-4 Bilastine 
• 1567835-74-8 2-(1-(4-bromophenethyl)piperidin-4-yl)-1-(2-ethoxyethyl)-1H-benzo[d]imidazole 

Relevant articles and documents

Cell-Based Drug Discovery: Identification and Optimization of Small Molecules that Reduce c-MYC Protein Levels in Cells

Elevated expression of the c-MYC oncogene is one of the most common abnormalities in human cancers. Unfortunately, efforts to identify pharmacological inhibitors that directly target MYC have not yet yielded a drug-like molecule due to the lack of any known small molecule binding pocket in the protein, which could be exploited to disrupt MYC function. We have recently described a strategy to target MYC indirectly, where a screening effort designed to identify compounds that can rapidly decrease endogenous c-MYC protein levels in a MYC-amplified cell line led to the discovery of a compound series that phenocopies c-MYC knockdown by siRNA. Herein, we describe our medicinal chemistry program that led to the discovery of potent, orally bioavailable c-MYC-reducing compounds. The development of a minimum pharmacophore model based on empirical structure activity relationship as well as the property-based approach used to modulate pharmacokinetics properties will be highlighted.

A PROCESS FOR THE PREPARATION OF A DERIVATIVE OF 2-METHYL-2'-PHENYLPROPIONIC ACID USING NEW INTERMEDIATES

The present invention deals with a preparation method of derivatives of methyl-2 '- phenylpropionic acid, e.g. the antihistamine bilastine of formula 9 that uses a new intermediate of formula 27 in the form of a base or salt. The intermediate reacts with

Synthesis and antihistaminic H1 activity of 1,2,5(6)-trisubstituted benzimidazoles

A number of benzimidazoles, having several substituents on the azole and benzene nuclei and C-2 (methylamino, ethylenediamine, morpholine, piperazine and piperidine) were prepared. Regioselective synthesis was designed for the N1-alkyl substituted benzimidazoles (14-15). X-Ray structure analysis of (14) was also revealed. Compounds were evaluated for their in vitro H1- antihistaminic activity in the isolated guinea-pig ileum method. The compound (11) exhibits best activity.